Beijing TopLead Biotech

TopLead Biotech is a clinical-stage biopharmaceutical company headquartered in Beijing, China, focused on developing next-generation small molecule drugs for autoimmune and inflammatory diseases. The company utilizes a proprietary structure-based drug design platform to create highly selective inhibitors for challenging targets, such as Tyrosine kinase 2 (TYK2). Its lead candidate, TL-011, is a potent and selective TYK2 inhibitor currently undergoing clinical trials for indications including psoriasis and lupus. TopLead is backed by prominent venture capital firms and aims to provide safer, more effective oral treatment options for patients worldwide.